naa a22 4500 510763200 CHVBK 20180411083147.0 cr unu---uuuuu 180411e20130601xx s 000 0 eng 10.1007/s12094-012-0952-6 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0952-6 Preoperative treatment with bevacizumab in combination with chemotherapy in patients with unresectable metastatic colorectal carcinoma [Elektronische Daten] [J. Figueras, S. Lopez-Ben, M. Alsina, J. Soriano, X. Hernandez-Yagüe, M. Albiol, R. Guardeño, A. Codina-Barreras, B. Queralt] Purpose: This prospective observational study assessed the efficacy of bevacizumab in combination with chemotherapy as preoperative treatment to downsize tumours for radical resection in patients with unresectable metastatic colorectal cancer (mCRC). Patients/methods: Patients with mCRC initially unresectable according to predefined criteria were included. Preoperative treatment consisted of bevacizumab (5mg/kg) combined with oxaliplatin- or irinotecan-based chemotherapy, which was followed by surgery in patients showing clinical benefit. Resection rate was the primary endpoint. Response rate (RR) and clinical benefit of preoperative chemotherapy, and overall survival (OS) were secondary endpoints. Results: A total of 120 eligible patients were included and received preoperative treatment. Chemotherapy was irinotecan-based in 73 (61%) patients, oxaliplatin-based in 25 (21%) and 22 (18%) patients received more than one line. A RR of 30% and a clinical benefit rate of 73% were observed with preoperative chemotherapy. Metastatic resection was possible in 61 (51%) patients. Median OS was 33months (95% CI 31-NAmonths) for patients undergoing surgery, and 15months (95% CI 11-25months) in non-operated patients. Thirty-five patients experienced 59 postoperative complications (morbidity rate 57%). Conclusion: Preoperative bevacizumab-based chemotherapy offers a high surgical rescue rate in patients with initially unresectable mCRC. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Bevacizumab nationallicence Metastatic colorectal cancer nationallicence Neoadjuvant chemotherapy nationallicence Postoperative morbidity nationallicence Surgical resection nationallicence Figueras J. Department of Surgery, "Dr Josep Trueta” Hospital, Av. de França s/n, 17007, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut Lopez-Ben S. Department of Surgery, "Dr Josep Trueta” Hospital, Av. de França s/n, 17007, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut Alsina M. Department of Oncology, Institut Catalá Oncologia (ICO), "Dr Josep Trueta” Hospital, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut Soriano J. Department of Radiology, Institut Diagnostic Imatge (IDI), "Dr Josep Trueta” Hospital, Girona, Spain aut Hernandez-Yagüe X. Department of Oncology, Institut Catalá Oncologia (ICO), "Dr Josep Trueta” Hospital, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut Albiol M. Department of Surgery, "Dr Josep Trueta” Hospital, Av. de França s/n, 17007, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut Guardeño R. Department of Oncology, Institut Catalá Oncologia (ICO), "Dr Josep Trueta” Hospital, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut Codina-Barreras A. Department of Surgery, "Dr Josep Trueta” Hospital, Av. de França s/n, 17007, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut Queralt B. Department of Oncology, Institut Catalá Oncologia (ICO), "Dr Josep Trueta” Hospital, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut Clinical and Translational Oncology Springer Milan 15/6(2013-06-01), 460-466 1699-048X 15:6<460 2013 15 12094 https://doi.org/10.1007/s12094-012-0952-6 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0952-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Figueras J. Department of Surgery, "Dr Josep Trueta” Hospital, Av. de França s/n, 17007, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut NATIONALLICENCE 700 1- Lopez-Ben S. Department of Surgery, "Dr Josep Trueta” Hospital, Av. de França s/n, 17007, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut NATIONALLICENCE 700 1- Alsina M. Department of Oncology, Institut Catalá Oncologia (ICO), "Dr Josep Trueta” Hospital, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut NATIONALLICENCE 700 1- Soriano J. Department of Radiology, Institut Diagnostic Imatge (IDI), "Dr Josep Trueta” Hospital, Girona, Spain aut NATIONALLICENCE 700 1- Hernandez-Yagüe X. Department of Oncology, Institut Catalá Oncologia (ICO), "Dr Josep Trueta” Hospital, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut NATIONALLICENCE 700 1- Albiol M. Department of Surgery, "Dr Josep Trueta” Hospital, Av. de França s/n, 17007, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut NATIONALLICENCE 700 1- Guardeño R. Department of Oncology, Institut Catalá Oncologia (ICO), "Dr Josep Trueta” Hospital, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut NATIONALLICENCE 700 1- Codina-Barreras A. Department of Surgery, "Dr Josep Trueta” Hospital, Av. de França s/n, 17007, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut NATIONALLICENCE 700 1- Queralt B. Department of Oncology, Institut Catalá Oncologia (ICO), "Dr Josep Trueta” Hospital, Girona Biomedical Research Institute (IdIBGi), Girona, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/6(2013-06-01), 460-466 1699-048X 15:6<460 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer